Iris Roth
Plus aucun poste en cours
Fortune : 576 713 $ au 30/04/2024
Profil
Iris Roth, former Vice President-Global Medicine at AstraZeneca PLC, Vice President-Medicine Development Leader at GlaxoSmithKline LLC, and Chief Operating Officer at Kartos Therapeutics, Inc. She also briefly served as Chief Operating Officer at Zentalis Pharmaceuticals, Inc. Dr. Roth holds an undergraduate degree from the University of California, Berkeley and a doctorate degree from The University of California, San Francisco.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2023 | 52 500 ( 0,07% ) | 576 713 $ | 30/04/2024 |
Anciens postes connus de Iris Roth
| Sociétés | Poste | Fin |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Directeur des opérations | 10/10/2023 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Directeur Technique/Scientifique/R&D | 01/02/2023 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Directeur des opérations | - |
Formation de Iris Roth
| University of California, Berkeley | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Health Technology |